Novelgen announced that it will issue 17,142 common shares at a price of KRW 175,000 per share for gross proceeds of KRW 2,999,850,000 on October 29, 2021. The transaction will include participation from BioPlus Co., Ltd. The company expects to close the transaction on November 1, 2021.